Identification of Tumor-Associated Antigens for Diagnosis and Therapy
First Claim
1. A pharmaceutical composition, comprising an agent which(I) inhibits expression or activity of a tumor-associated antigen and/or(II) has tumor-inhibiting activity, and is selective for cells expressing or abnormally expressing a tumor-associated antigen and/or(III) when administered, selectively increases the amount of complexes between an MHC molecule and a tumor-associated antigen or a part thereof, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions,(c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and(d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
5 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
-
Citations
50 Claims
-
1. A pharmaceutical composition, comprising an agent which
(I) inhibits expression or activity of a tumor-associated antigen and/or (II) has tumor-inhibiting activity, and is selective for cells expressing or abnormally expressing a tumor-associated antigen and/or (III) when administered, selectively increases the amount of complexes between an MHC molecule and a tumor-associated antigen or a part thereof, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: -
(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c). - View Dependent Claims (2, 3, 4, 5, 6, 16, 17, 18, 19, 20, 31, 37)
-
-
7. A pharmaceutical composition, comprising one or more components selected from the group consisting of:
-
(i) a tumor-associated antigen or a part thereof, (ii) a nucleic acid which codes for a tumor-associated antigen or a part thereof, (iii) an antibody which binds to a tumor-associated antigen or a part thereof, (iv) an antisense nucleic acid which hybridizes specifically with a nucleic acid coding for a tumor-associated antigen, (v) an siRNA directed against a nucleic acid coding for a tumor-associated antigen, (vi) a host cell which expresses a tumor-associated antigen or a part thereof, and (vii) isolated complexes between a tumor-associated antigen or a part thereof and an MHC molecule, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of; (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c). - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15)
-
-
21. A method of diagnosing or monitoring a disease characterized by expression or abnormal expression of a tumor-associated antigen, wherein the method comprises the step of detecting or determining the amount of:
-
(i) of a nucleic acid which encodes for the tumor-associated antigen or of a part thereof, or (ii) of the tumor-associated antigen or of a part thereof, or (iii) of an antibody to the tumor-associated antigen or a part thereof or (iv) of T lymphocytes which are specific to the tumor-associated antigen or to a part thereof in a biological sample isolated from a patient, with the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of; (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c);
or(v) combinations of (i), (ii), (iii), or (iv). - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 33, 38)
-
-
32. A method of treating, preventing, diagnosing or monitoring a disease characterized by expression or abnormal expression of a tumor-associated antigen, wherein the method comprises the step of administering an antibody binding to the tumor-associated antigen or to a part thereof and coupled to a therapeutic or diagnostic agent, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of:
-
(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
-
-
34. A method of treating a patient having a disease characterized by expression or abnormal expression of a tumor-associated antigen, wherein the method comprises the steps of:
-
(i) providing a sample containing immunoreactive cells, (ii) contacting the sample with a host cell expressing the tumor-associated antigen or a part thereof, under conditions which favor production of cytolytic or cytokine-releasing T cells against the tumor-associated antigen or the part thereof, and (iii) introducing the cytolytic or cytokine-releasing T cells into the patient in an amount suitable for lysing cells expressing the tumor-associated antigen or a part thereof, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of; (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c). - View Dependent Claims (35, 36, 49)
-
-
39. An agent, which binds specifically to a protein or polypeptide or to a part thereof, the protein or polypeptide being encoded by a nucleic acid selected from the group consisting of:
-
(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c). - View Dependent Claims (40, 41, 42, 46, 47)
-
-
43. An antibody, which binds selectively to a complex of:
-
(i) a protein or polypeptide or a part thereof, and (ii) an MHC molecule to which the protein or polypeptide or the part thereof binds, with the antibody not binding to (i) or (ii) alone and the protein or polypeptide being encoded by a nucleic acid selected from the group consisting of; (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c). - View Dependent Claims (44, 45, 50)
-
-
48. A kit for detecting expression or abnormal expression of a tumor-associated antigen, wherein the kit comprises agents for detecting or determining the amount
(i) of a nucleic acid which codes for the tumor-associated antigen or of a part thereof, and/or (ii) of the tumor-associated antigen or of a part thereof, and/or (iii) of antibodies which bind to the tumor-associated antigen or to a part thereof, and/or (iv) of T cells which are specific for a complex between the tumor-associated antigen or a part thereof and an MHC molecule, the tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: -
(a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs;
1, 5, 9, 13, 17, 21, 25, 28, 30, 35, 39, 41, 45, 49, 61, 62, and 64-67, a part or derivative thereof,(b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions, (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b), and (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
-
Specification